Immuneering Corporation (IMRX) Total liabilities 2020–2023
Immuneering Corporation (IMRX) total liabilities at each fiscal year-end, per SEC filings.
$12.0MFY2023 · since FY2020: $2.8M → $12.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | $12.0M | -4.1% |
| FY2022 | $12.5M | +16.7% |
| FY2021 | $10.7M | +282.9% |
| FY2020 | $2.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMRX financial trends
IMRX RevenueIMRX Net incomeIMRX Net marginIMRX Gross profitIMRX Gross marginIMRX Operating incomeIMRX Operating marginIMRX Operating cash flowIMRX Free cash flowIMRX Capital expendituresIMRX Return on equityIMRX Stock buybacksIMRX Dividends paidIMRX Total assetsIMRX Shareholders’ equityIMRX overview →